- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01052792
Bioequivalence Study of Naproxen Sodium 550 mg Tablets Under Fed Conditions
January 19, 2010 updated by: Dr. Reddy's Laboratories Limited
Open Label Randomised,Two-treatment,Two-period,Two-sequence,Single-dose, Crossover,Comparative Bioequivalence Study of Naproxen Sodium 550 mg Tablets With ANAPROX® DS 550 mg Tablets in Healthy,Adult, Human Subjects Under Fed Conditions
An open label randomised, two-treatment,two-period, two-sequence, single-dose, crossover, comparative bioequivalence study.
Study Overview
Detailed Description
The study was an open label, randomised, two-treatment,two-period, two-sequence, single-dose, crossover,comparative bioequivalence study of Naproxen Sodium 550 mg tablets (containing naproxen 500 mg) manufactured by Dr. Reddy's Laboratories, ltd, Generics, India compared with ANAPROX® DS 550 mg tablets (containing naproxen 500 mg) of Roche Pharmaceuticals, Roche Laboratories Inc. 340 Kingsland Street, New Jersey; in healthy,adult, human subjects under fed conditions with a wash out period of 10 days between two periods.
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400 013
- Wellquest Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 43 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy human subjects within the age range of 18 to 45 years.
- Non-smokers since at least six months.
- Willingness to provide written informed consent to participate in the study.
- Body-mass index of ≥ 18.5 kg/m2 and ≤ 24.9 kg/m2, witQ body weight not less than 50 kg.
- Absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluations, medical history or physical examination during the screening.
- Normal 12-lead ECG or one with abnormality considered to be clinically insignificant.
- Normal chest X-ray PA view.
- Comprehension of the nature and purpose of the study and compliance with the requirement of the protocol.
Female Subjects:
- of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s) such as condoms, foams jellies, diaphragm, intrauterine device {IUD}, or abstinence or postmenopausal for at least 1 year, or surgically sterile {bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject.
Exclusion Criteria:
- Personal/family history of allergy or hypersensitivity to Naproxen sodium or allied drugs.
- Past history of anaphylaxis or angioedema.
- Any major illness in the past three months or any clinically significant ongoing chronic medical illness e.g. congestive heart failure, hepatitis, pancreatitis etc.
- Presence of any clinically significant abnormal values during screening e.g significant abnormality of liver Function Test (LFT), Renal (kidney) Function Test (RFT), etc.
- Any cardiac, renal or liver impairment any other organ or system impairment.
- History of seizure or psychiatric disorders.
- Presence of disease markers of HIV 1 and 2, and hepatitis B and C virus.
- Consumption of alcohol for more than two years, or consumption of more than three alcoholic drinks per day or consumption of alcohol within 48 hours prior to dosing and during the study {one drink is equal to one unit of alcohol {one glass wine half pint beer, and one measure (one ounce) of spirit].
- Consumption of xanthine containing derivatives (coffee, tea, cola drinks, chocolate) within 48 hours before check-in of each period.
- Use of any recreational drug or a history of drug addiction.
- Participation in any clinical trial within the past 3 months.
- Inaccessibility of veins in left and right arm.
- Donation of blood (one unit or 350 mL) within 3 months prior to receiving the first dose of study medication.
- Receipt of any prescription drug therapy within four weeks or over-the-counter {OTC) drugs within two weeks prior to receiving the first dose of study medication or repeated use of drugs within the last four weeks.
- An unusual diet, for whatever reason e.g. low sodium diet for two weeks prior to receiving any medication and through out subject's participation in the study.
- Consumption of grapefruit-containing food or beverages within 7 days prior to receiving the first dose of study medication in both the periods.
- Recent history of dehydration from diarrhoea, vomiting or any other reason within a period of 24 hours prior to the study.
- Female volunteers demonstrating a positive pregnancy screen or currently breast-feeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Naproxen Sodium 550 mg Tablets
Naproxen Sodium 550 mg Tablets of Dr. Reddy's Laboratories Limited
|
Naproxen Sodium Tablets 550 mg
Other Names:
|
Active Comparator: Anaprox DS 550mg Tablets
Anaprox DS 550mg Tablets of Roche Pharmaceuticals Inc
|
Naproxen Sodium Tablets 550 mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bioequivalence based on Cmax and AUC parameters
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Dr. Umesh Dhakate, MBBS, Wellquest Clinical Research
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2006
Primary Completion (Actual)
May 1, 2006
Study Completion (Actual)
June 1, 2006
Study Registration Dates
First Submitted
January 8, 2010
First Submitted That Met QC Criteria
January 19, 2010
First Posted (Estimate)
January 20, 2010
Study Record Updates
Last Update Posted (Estimate)
January 20, 2010
Last Update Submitted That Met QC Criteria
January 19, 2010
Last Verified
January 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nutrition Disorders
- Malnutrition
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Gout Suppressants
- Naproxen
Other Study ID Numbers
- CR-BE-138-NAPR-2005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Naproxen Sodium
-
Johnson & Johnson Consumer Inc., McNeil Consumer...Completed
-
BayerCompletedPain, PostoperativeUnited States
-
Johnson & Johnson Consumer Inc., McNeil Consumer...Completed
-
Genta IncorporatedCompleted
-
Huazhong University of Science and TechnologyWithdrawnType1 Diabetes MellitusChina
-
Johnson & Johnson Consumer Inc., McNeil Consumer...CompletedPost-operative Dental PainUnited States
-
Genta IncorporatedCompleted
-
McNeil ABCompleted
-
Johnson & Johnson Consumer Inc. (J&JCI)Recruiting